Trial Talk

Optimisation immunotherapy clinical trials investigate ways of reducing the intensity of immunotherapy cancer treatment. This could be beneficial for patients’ quality of life. But these trials can be challenging to run, as patients may be concerned about the impact that reducing the intensity of treatment could have on the cancer.

This episode of the Trial Talk podcast focuses on the MRC Clinical Trials Unit at UCL’s OPTIC study, which explores how people with cancer feel about taking part in optimisation immunotherapy trials. Clinical Fellow Sophie Merrick discusses the main barriers that patients face and recommendations to address them.

Resources:
•OPTIC study page: www.mrcctu.ucl.ac.uk/studies/all-st…/refine/optic/
•OPTIC results paper: www.nature.com/articles/s41416-024-02756-x.pdf
•REFINE podcast episode: on.soundcloud.com/Fe3C76csHkgCg2or5

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: bit.ly/4c9SfAr

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Date of episode recording: 2024-06-18T00:00:00Z
Duration: 00:25:23
Language of episode: English
Presenter: Berta Terre-Torras
Guests: Sophie Merrick
Producer: Berta Terre-Torras

What is Trial Talk?

The Trial Talk podcast explores how our work at the UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL) is improving health in the UK and around the world. Through conversations with world-leading experts, researchers, and patient representatives, we take listeners inside the studies we run.